Why the study?
Can human embryonic stem cell-derived cardiomyocytes be used to assess both functional and structural cardiotoxicity of drugs?
Can human embryonic stem cell-derived cardiomyocytes be used to assess both functional and structural cardiotoxicity of drugs?
Combining functional and structural assays using hESC-CMs provides a more comprehensive and holistic approach to preclinical cardiotoxicity risk assessment.
Authors
No takes yet. Share an insight, caveat, or question.
May advance preclinical cardiotoxicity screening with hESC-CMs; leaves open clinical translation pending validation.
Clements et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: